Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in previously ...
Acalabrutinib, made by the drug company AstraZeneca and marketed under the brand name Calquence, works by blocking an enzyme called Bruton’s tyrosine kinase (BTK), which helps cancerous B cells ...
who are ineligible for autologous hematopoietic stem cell transplantation (HSCT), according to a news release from AstraZeneca. Importantly, Calquence is now the first and only Bruton tyrosine kinase ...
AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...
Learn more about whether AstraZeneca PLC or Intra-Cellular Therapies, Inc. is a better investment based on AAII's A+ Investor ...
AstraZeneca Q4 revenue rose 18% to $14.89 ... Tagrisso sales were up 20% to $1.70 billion (21% at CER), Calquence sales increased 20% to $808 million, Lynparza sales increased 46% (+47%) to ...
AstraZeneca PLC has a 12-month low of $62. ... The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta ...
AstraZeneca’s other drugs, Fasenra, Calquence, Breztri and newer products, asthma drug Tezspire, breast cancer drug Truqap and lupus drug Saphnelo (anifrolumab) are likely to have contributed to ...
Allworth Financial LP boosted its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 12.9% in the fourth quarter, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback